Business · 02/09/2010Updated: 10/17/2026 · 1 min read
FDA Sets Regulatory Review Period for Pfizer's Pristiq Patent Extension
Summary
The US Food and Drug Administration (FDA) has determined the regulatory review period for Pfizer's patent extension application for Pristiq, a medication used to treat depression and anxiety disorders.
Original source language: Federal Register — Health and Human ServicesOpen original release →